CELU vs. MVST, ATIP, LOTZ, CMAX, ENTA, IMMP, EBS, FHTX, ACRV, and XBIT
Should you be buying Celularity stock or one of its competitors? The main competitors of Celularity include Microvast (MVST), ATI Physical Therapy (ATIP), CarLotz (LOTZ), CareMax (CMAX), Enanta Pharmaceuticals (ENTA), Immutep (IMMP), Emergent BioSolutions (EBS), Foghorn Therapeutics (FHTX), Acrivon Therapeutics (ACRV), and XBiotech (XBIT).
Celularity (NASDAQ:CELU) and Microvast (NASDAQ:MVST) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings, risk and community ranking.
In the previous week, Celularity had 1 more articles in the media than Microvast. MarketBeat recorded 2 mentions for Celularity and 1 mentions for Microvast. Microvast's average media sentiment score of 1.87 beat Celularity's score of 0.44 indicating that Microvast is being referred to more favorably in the news media.
Celularity has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Comparatively, Microvast has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500.
19.0% of Celularity shares are held by institutional investors. Comparatively, 20.7% of Microvast shares are held by institutional investors. 20.7% of Celularity shares are held by insiders. Comparatively, 31.3% of Microvast shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Microvast has a consensus target price of $4.50, indicating a potential upside of 1,103.53%. Given Microvast's higher probable upside, analysts plainly believe Microvast is more favorable than Celularity.
Celularity has higher earnings, but lower revenue than Microvast.
Microvast received 2 more outperform votes than Celularity when rated by MarketBeat users. However, 42.11% of users gave Celularity an outperform vote while only 41.67% of users gave Microvast an outperform vote.
Microvast has a net margin of -29.79% compared to Celularity's net margin of -1,226.72%. Celularity's return on equity of 30.79% beat Microvast's return on equity.
Summary
Microvast beats Celularity on 9 of the 15 factors compared between the two stocks.
Get Celularity News Delivered to You Automatically
Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Celularity Competitors List
Related Companies and Tools
